Sellas Life Sciences Group, Inc. (SLS), Wednesday announced positive data from preclinical studies identifying ASXL1 mutation as key predictor of SLS009, a highly selective CDK9 inhibitor, response in solid cancers.
The data revealed that high SLS009 efficacy was observed in 67 percent of ASXL1 mutated cell lines compared to 0 percent in non-ASXL1 mutated cancer.
In colorectal carcinomas with high-level microsatellite instability, and non-small cell lung cancer, high efficacy was observed in ASXL1 mutated cell lines compared to the non-ASXL1 mutated cell lines.
The biotechnology company added that SLS009 outperformed positive control in 5 out of 9 cell lines, establishing itself as a highly effective therapeutic candidate.
Currently, Sellas's stock is moving up 2.49 percent, to $1.23 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.